Peptide News Digest

WHO's First Adult Type 1 Diabetes Guidelines, Wegovy Pill Real-World Data, Costs Drive GLP-1 Quitting

WHO issues its first adult type 1 diabetes guidelines, Wegovy pill users lose 6.2% in three months, and cost rivals vomiting as a reason to stop GLP-1s.

11 stories · Covering regulatory, industry, research, clinical-trials

Editor's Note

World Diabetes Day on November 14 put insulin, a peptide hormone first used as a drug more than 100 years ago, back in the news. The WHO issued its first guidelines for adults with type 1 diabetes, written to apply even where insulin and glucose testing are scarce. Ontario said it will stop making people inject insulin for a year before it pays for a pump, and an Edmonton clinic now lets Albertans book a pump consultation without a referral. A Chinese records study found a cheaper biosimilar insulin aspart controlled blood sugar about as well as NovoRapid. On the GLP-1 side, cost keeps shaping who stays on treatment. A USC survey presented at ObesityWeek found that paying $51 or more a month was a stronger predictor of quitting than vomiting. Novo reported that people who stayed on its Wegovy pill for three months lost 6.2% of their weight. A Danish registry study points to diabetes itself, not the drugs, behind a higher preterm birth risk after GLP-1 use around conception. Two lab studies tested peptides that help antibiotics get into bacteria or calm lung inflammation during infection.

WHO Issues Its First Guidelines for Adults With Type 1 Diabetes, Backing Several Daily Insulin Injections and Human Insulin

Marking World Diabetes Day on November 14, the World Health Organization published its first guidelines on diagnosing and managing type 1 diabetes in adults, designed to apply in low-resource, emergency, and humanitarian settings. WHO recommends insulin injections several times a day with doses adjusted to blood glucose, calls human insulin an appropriate and effective option, and says urine glucose testing can be considered where blood testing is unavailable. About 9.5 million people lived with type 1 diabetes in 2025, with 500,000 more diagnosed that year.

Ontario Will Drop Its Rule That People With Type 1 Diabetes Inject Insulin for a Year Before It Funds a Pump

Starting February 1, 2027, Ontario's Assistive Devices Program will no longer require applicants to use insulin injections for one year before receiving pump funding, and grant renewals will move from every year to every two years, the Sydenham Current reported. The program fully funds approved pumps and pays $2,400 a year for supplies. In 2025-26 it spent about $95 million on pumps and supplies for nearly 24,000 people. The province announced the change ahead of World Diabetes Day.

Global News: Edmonton Clinic Opens Alberta's First Insulin Pump Program That Patients Can Join Without a Referral

The Edmonton Diabetes and High Risk Foot Clinic now lets Albertans with type 1 diabetes book an insulin pump consultation directly, starting with a phone call with a nurse practitioner, Global News reported. The clinic says it has no waitlist and most patients can be on a pump in about two months, compared with waits of up to two years elsewhere. Alberta's health ministry said more than 7,000 people used the province's funded pump program in 2025-26, up from about 4,000 in 2021-22.

Biosimilar Insulin Aspart Rapilin Matched NovoRapid on Blood Sugar in 229 Chinese Patients With Type 1 Diabetes

In a retrospective study of records from 34 hospitals in China, published in Diabetes Therapy, HbA1c fell by an adjusted 1.90 percentage points on the biosimilar Rapilin (116 patients) and 1.59 points on Novo Nordisk's NovoRapid (113 patients). The difference was not statistically significant. Half of the patients were children or adolescents, and the authors reported similar dose stability and safety. Because the study was not randomized, it cannot rule out differences between the patients who received each insulin.

Reuters: People Who Stayed on Novo's Wegovy Pill for Three Months Lost 6.2% of Their Weight in Real-World Data

Novo Nordisk's analysis of 5,872 adults on the Ro telehealth platform who had never used a weight-loss drug and stayed on the daily Wegovy pill for three months found average weight loss of 6.2%, or 6.3 kg from a starting weight of 103.0 kg, Reuters reported via CTV News. About three in five lost at least 5% and roughly one in six lost at least 10%. Novo's scientific chief Martin Holst Lange said the result broadly matched the 5.5% seen at 12 weeks in the pill's late-stage trial.

USC Survey: Paying $51 or More a Month Predicted Stopping a GLP-1 More Strongly Than Vomiting Did

Presenting at ObesityWeek, USC's Alison Sexton Ward reported that 1,256 of 9,139 Understanding America Study respondents had ever used a GLP-1, and 43% of those taking it only for weight loss had no insurance coverage for it, Medscape reported. Out-of-pocket costs of $51 or more a month raised the hazard of stopping 2.7-fold compared with no copay, versus 2.1-fold for vomiting, while having diabetes halved it. Discontinuation reached 22.1% at 12 months and 33.4% at 24 months.

CagriSema REDEFINE 1 Post Hoc Analysis: Early Responders Lost 25.4% of Their Weight at 68 Weeks Versus 17.8% for Slower Responders

In a post hoc analysis that Novo Nordisk announced on November 15 and presented at ObesityWeek, 67.8% of people on CagriSema 2.4 mg/2.4 mg lost at least 5% of their weight by week 8. These early responders lost an average of 25.4% by week 68, compared with 17.8% for those who responded later, based on observed on-treatment data the company calls hypothesis-generating. In a separate post hoc analysis, 73.1% on CagriSema versus 49.1% on placebo reported a meaningful improvement in physical function. An FDA decision is expected in the fourth quarter of 2026.

Danish Registry Study of 756,636 Pregnancies Ties Higher Preterm Birth Risk After Early GLP-1 Exposure to Diabetes, Not Weight-Loss Use

Copenhagen researchers identified 529 pregnancies in which the mother filled a liraglutide or semaglutide prescription within eight weeks before or after the start of her last menstrual period. Among women using the drugs for diabetes, the adjusted odds of preterm birth were 1.70 times higher with liraglutide and 1.84 times higher with semaglutide than in matched unexposed pregnancies; among women using them for weight management, there was no association. The study, published in Human Reproduction Open in March and publicized by the European Society of Human Reproduction and Embryology on November 13, cannot establish cause.

Warrington Guardian: AAH Pharmaceuticals Employee Charged With Stealing Mounjaro From the Distributor in England

Jamie Taylor, 32, of Crewe, has been charged with theft by an employee and handling stolen goods between January 26 and March 13, the Warrington Guardian reported. He is alleged to have stolen the weight-loss drug Mounjaro while working at AAH Pharmaceuticals, a healthcare distributor based at Winwick Quay in Warrington. He appeared at Warrington Magistrates' Court, has not yet entered a plea, and is due back in court on November 24.

Bose Institute Peptides With No Antibacterial Activity of Their Own Made Half-Dose Antibiotics Work Better Against Gram-Negative Bacteria

Kolkata researchers designed cationic 23-amino-acid peptides that clump Gram-negative bacteria and form amyloid fibrils on their outer membranes, which helps antibiotics get inside. The peptides assemble only in the presence of lipopolysaccharide, a component of the bacterial outer membrane. In their infection model, a peptide plus a half dose of antibiotic lowered bacterial burden and disease severity more than either treatment alone, the team reported in Small.

University of Oklahoma's SPA4 Peptide Cut Damage Signals and Inflammatory Cells in the Lungs of Mice Infected With Pseudomonas

In mice infected with Pseudomonas aeruginosa, treatment with the 20-amino-acid SPA4 peptide, which modulates host defenses that depend on the immune receptor TLR4, lowered lung levels of damage-associated molecules compared with a vehicle. HMGB-1 fell to 11,758 from 15,896 ng per gram of lung, and hyaluronan to 34,157 from 53,644 ng. Lung tissue showed fewer infiltrating cells, though TLR4 levels themselves did not change, the researchers reported in PLOS One.